Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Salestools Logo

Salestools

#1 AI-agent til salgsteams og Go-to-Market-teams. Sælg mere, hurtigere, med mindre indsats.

Produkt

  • AI-salgsagenter
  • Intent-data
  • Teknologidata
  • Besøgssporing
  • Co-Pilot
  • Socialt salg

Løsninger

  • Kundeservice
  • E-handel
  • SaaS
  • Enterprise
  • Lille virksomhed

Ressourcer

  • Rapporten
  • Dokumentation
  • API-reference
  • Hjælpecenter
  • Blog
  • Case-studier
  • Webinarer

Virksomhed

  • Om os
  • Karriere
  • Presse
  • Kontakt
  • Partnere

Vores lokationer

  • New York, HQ
  • Bukarest, AI-forskningslaboratorium
  • Zug, Schweiz

© 2026 Salestools. Alle rettigheder forbeholdes.

Datavilkår & sikkerhedPrivatlivspolitikServicevilkårAcceptable Use
Alle systemer operationelle
Salestools LogoSalestools
Salestools AI-agenter
Løsninger
Ressourcer
Virksomhed
Priser
Back to Reports
Biotech

Biogen

Biogen raises $35B Public at $38B valuation

225 Binney Street, Cambridge, MA 02142January 1, 20241 min read
Total Raised
$35B
Valuation
$38B
Latest Round
Public
Employees
9000+

Biogen: Public Funding Round

Biogen has successfully raised $35B in Public funding, reaching a valuation of $38B.

Company Overview

Biotechnology company

Funding Details

The Public round was led by Public.

Company Information

  • Headquarters: 225 Binney Street, Cambridge, MA 02142
  • Founded: 1978
  • Employees: 9000+
  • Category: Biotech

Investment

Biogen plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Public: Verified investor in Public

Company Info

Headquarters
225 Binney Street, Cambridge, MA 02142
Founded
1978
Team Size
9000+
Last Round
$35B(Jan 2024)

Investors (1)

P
PublicLead
Lead Investor
Verified investor in Public

Topics

verified(3079)real-funding(3079)public(927)biogenbiotech225-binney-street

Share

Related Reports

Biotech
AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

David Chen
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free